Russian Federation: Changes To The Rules For Forming Lists Of Medicines Become Effective

Last Updated: 20 November 2018
Article by Sergey Klimenko

On October 29, 2018, the Government of the Russian Federation approved the changes1 to the Rules for Producing the Lists of Medicines and Minimum range of medicines required for medical care that were adopted on 28 August 2014 (the "Revised Rules").

Thus, as from November 9, 2018, the RF Health Ministry committee is to follow the Revised Rules when producing the said lists.

Dentons Life Sciences practice would like to acquaint you with the main provisions of the Revised Rules, which are set forth below.

1. Criteria revised for producing the list of essential medicines

According to the Revised Rules, the list is produced with consideration for, among other things, clinical evaluation results on prevention, diagnostic, treatment and rehabilitation methods.

According to the provisions of the Federal Law on Fundamental Health Care Principles in the Russian Federation (No. 323-FZ of Nov. 21, 2011), clinical evaluation involves the practical application of developed but previously unapplied prevention, diagnostic, treatment and rehabilitation methods for delivering health care in order to substantiate their efficacy. There are certain features to health care that is delivered in the context of a clinical evaluation.

The Revised Rules also clarify the wording of the criterion on the use of a medicine for diagnostic, prevention, treatment and rehabilitation purposes when delivering health care in the event of illnesses and conditions, including the most prevalent ones in the distribution of disease in the Russian Federation (the reference to syndromes has been removed).

A listed medicine's therapeutic equivalence to medicines with a similar mechanism of pharmacological action has been removed from the list of mandatory criteria for a medicine to be included in the said list.

2. Grounds added for delisting medicines

Based on two new grounds, a medicine can be removed from the list of essential medicines, the list of high-cost medicines and the list of medicines for eligible beneficiaries and staple medicines, if:

  • a chief external expert at the Health Ministry of Russia presents a research-based recommendation in relation thereto following the comprehensive assessment thereof;
  • the manufacturer's maximum selling price for the medicine is not registered within six months after it is included in the list.

An alternative medicine being listed, the emergence of information about a medicine's toxicity or frequent undesirable side effects, discontinuation of use in the Russian Federation, revocation of the state registration, stoppage of production/deliveries of a medicine or its not being on the market in the Russian Federation for longer than one year – the grounds provided in the previous version of the rules will still be applicable.

3. Single-agent and combination medicines

The listing and minimum assortment of these medicines were formerly not expressly mentioned in the rules.

The Revised Rules now include a section 6(2), providing that single-agent medicines are to be included in these lists by default, and combination medicines are only to be listed when the results of a comprehensive assessment have demonstrated them to be use- and cost-beneficial compared with single-agent medicines. In case of such listing, all of the single-agent medicines registered in the Russian Federation that make up such combination are listed simultaneously.

4. Changes to the membership of the Health Ministry of Russia committee and meeting attendees

According to the Revised Rules, the Health Ministry of Russia committee no longer includes members from the RF Finance Ministry and the Federal Agency for Scientific Organizations, which owing to the dissolution of the latter has been replaced by the Science and Higher Education Ministry of Russia.

Previously, at the committee's initiative, representatives from other federal executive authorities, as well as nongovernmental organizations active in health care and pharmaceuticals and consumer protection in these industries, could be invited to a meeting.

Now the approach is for the prospective meeting attendees themselves to initiate the process; these include: a representative of a pharmaceutical entity and/or nongovernmental organization active in health care and pharmaceuticals and consumer protection in these industries, as well as representatives of other federal executive authorities. To do so, they have to file a respective written request with the committee at least five business days prior to the meeting date.

5. New procedure for entities to forward proposals for medicine listings and new rules for medicine assessments

According to the previous version of the rules, applicants forwarded their annual (no later than March 31) proposals for the listing of particular medicines to the Health Ministry of Russia by completing a special form in hard copy and electronically. With the Revised Rules taking effect, these proposals are now forwarded in electronic form only and no later than the first day of the first month of the quarter.

The 15-day period that had been allotted to the committee to review the set of documents received has been cut nearly in half – to seven business days.

That being said, if a submitted document's format technically prevents it from being opened, this could be grounds for the committee to reject the applicant's proposal; likewise if the applicant has resubmitted documents during a calendar year on which the committee has already issued a rejection in the current year or which have already undergone comprehensive evaluation (except for immediate amendments in accordance with RF Government instructions).

The report on the documentary review when a proposal is rejected is forwarded to the applicant electronically within up to three business days (formerly, seven days). A refined proposal with the faults eliminated may be resubmitted to the committee by the applicant within 10 business days.

Next, the committee forwards an applicant's accepted proposal to the federal state budgetary institution Health Care Quality Assessment and Control Center (abbreviated as FGBU TsEKKMP in Russian) and, as before, to the industry-specific state federal educational establishment and/or pharmaceutical research organization under the jurisdiction of the Health Ministry of Russia or the Science and Higher Education Ministry of Russia for comprehensive evaluation and production of the relevant report. Then, the set of documents together with this report is forwarded by the committee to a chief expert for the preparation of a research-based recommendation on listing the medicine. With regard to producing the list of required medicines, this set of documents is forwarded to at least two chief experts subject to their area of competence.

Committee meetings are now held before the 10th day of the second month of the quarter after that in which a proposal is submitted. Meanwhile, the committee may consider no more than 15 medicines at a single meeting.

The Revised Rules also include, among other things, new Appendixes 1–9:

  • form of proposal for including a medicine in the lists of medications and required medicines;
  • form of report on the documentary review of a proposal for inclusion (removal) of a medicine in (from) the lists of medications and required medicines;
  • special requirements for the methodological quality of economic medicine evaluations and studies analyzing budgetary system impacts, which were not present previously;
  • integrated comprehensive medicine rating scales;
  • form of report on the analysis of information on a medicine's comparative clinical efficacy and safety and assessment of the economic consequences of its use;
  • form of report on the analysis of the methodological quality of economic medicine evaluations and studies analyzing budget impacts on the budgetary system of the Russian Federation, and also studying additional consequences of the use of a medicine, and form of research-based recommendation for inclusion (removal, rejection) of a medicine in the lists of medications and required medicines.

The Revised Rules are an attempt to streamline the process of producing the lists of medications and required medicines, providing for shortened timeframes and creating a more transparent process for evaluating an applicant's proposals.


1. RF Government Resolution No. 1283 of Oct. 29, 2018, "On amending the Rules for Producing the Lists of Medicines and Minimum range of medicines required for medical care".

About Dentons

Dentons is the world's first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world's largest law firm, Dentons' global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions